Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often ...

Exosomal siMecA (an siRNA designed to target the mecA gene) can downregulate the mecA gene which encodes the penicillin-binding protein 2a (PBP2a), a protein at the heart of the drug-resistance ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) therapeutics across several disease areas. The collaboration and license ...

With Alzheimer's in its sights, Alnylam shares data on getting siRNA to targets beyond the liver By Nick Paul Taylor Jun 7, 2022 8:00am Alnylam siRNA Alzheimer's drugs drug delivery ...

Generation Bio announces new programs using ctLNP for targeted siRNA delivery in T cell-driven autoimmune diseases, aiming for IND submission in 2026. Development of novel siRNA therapeutics using ...

Atlas spin-off aims to develop siRNA-ligand conjugates for the kidney Judo Bio is targeting a historically difficult organ to drug by Rowan Walrath October 7, 2024 3 min read ...